4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 10, 2009, Pages 2683-2687

  Parmenon, Cécile ^a   Guillard, Jérôme ^a   Caignard, Daniel Henri ^b   Hennuyer, Nathalie ^c   Staels, Bart ^c   Audinot Bouchez, Valérie ^d   Boutin, Jean Albert ^d   Dacquet, Catherine ^e   Ktorza, Alain ^e   Viaud Massuard, Marie Claude ^a  

^a UFR des Sciences Pharmaceutiques   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

^d Division de Recherche Pharmacologie Moléculaire et Cellulaire   (France)

^e INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Oxime; PPARs; Terahydroquinoline

Indexed keywords

1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; 2 HYDROXYACID; 4,4 DIMETHYL 1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; OXIME DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TESAGLITAZAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; MICE; OXIMES; PPAR ALPHA; PPAR GAMMA; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 65349174619     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.143     Document Type: Article

References (22)

1. Mangelsdorf D.J., and Evans R.M. Cell 83 (1995) 841
2. Isseman I., and Green S. Nature 347 (1990) 645
3. Berger J., and Moller D.E. Annu. Rev. Med. 53 (2002) 409
4. Staels B., and Fruchart J.-C. Diabetes 54 (2005) 2460
5. Berger J.P., Akiyama T.E., and Meinke P.T. Trends Pharmacol. Sci. 26 (2005) 244
6. Reifel Miller A. Drug Dev. Res. 67 (2006) 574
7. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. J. Med. Chem. 43 (2000) 527
8. Henke B.R. J. Med. Chem. 47 (2004) 4118
9. Lehmann J.M., Moore M.B., Smith-Oliver T.A., Wilkinson W.O., Willson T.M., and Kliewer S.A. J. Biol. Chem. 270 (1995) 12953
10. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., and Lehmann J.M. J. Med. Chem. 39 (1996) 665
11. Lohray B.B., Lorhay V.B., Bajji A.C., Kalchar S., Poondra R.R., Padakanti S., Chakrabarti R., Vikramadithyan R.K., Misra P., Juluri S., Mamidi R.N.V.S., and Rajagopalan R. J. Med. Chem. 44 (2001) 2675
12. Sauerberg P., Petterson I., Jeppesen L., Bury P.S., Mogensen J.P., Wassermann K., Brand C.L., Sturis J., Wöldike H.F., Fleckner J., Anderson A.S.T., Mortensen S.B., Anders-Svensson L., Rasmussen H.B., Lehmann S.V., Polivka Z., Sindelar K., Panajotova V., Ynddal L., and Wulff E. J. Med. Chem. 45 (2002) 789
13. Ebdrup S., Petterson I., Rasmussen H.B., Deussen H..J., Frost-Jensen A., Mortensen S.B., Fleckner J., Pridal L., Nygaard L., and Sauerberg P. J. Med. Chem. 46 (2003) 1306
14. Devasthale P.V., Chen S., Jeon Y., Qu F., Shao C., Wang W., Zhang H., Farreley D., Golla R., Grover G., Harrity T., Ma Z., Moore L., Ren J., Seethala R., Cheng L., Sleph P., Sun W., Tieman A., Wetterau J.R., Doweyko A., Chandrasena G., Chang S.Y., Humphreys J.R., Sasseville V.G., Biller S.A., Ryono D.E., Selan F., Harihanan N., and Cheng P.T.W. J. Med. Chem. 48 (2005) 2248
15. Koyama H., Miller D.J., Boueres J.K., Desai R.C., Jones A.B., Berger J.P., MacNaul K.L., Kelly L.J., Doebber T.W., Wu M.S., Zhou G., Wang P.R., Ippolito M.C., Chao Y.S., Agrawal A.K., Franklin R., Heck J.V., Wright S.D., Moller D.E., and Sahoo S.P. J. Med. Chem. 47 (2004) 3255
16. Shi G.Q., Dropinski J.F., McKeever B.M., Xu S., Becker J.W., Berger J.P., MacNaul K.L., Elbrecht A., Zhou G., Doebber T.W., Wang P., Chao Y.S., Forrest M., Heck J.V., Moller D.E., and Jones A.B. J. Med. Chem. 48 (2005) 4457
17. Gervois P., Fruchart J.-C., and Staels B. Int. J. Clin. Pract. 58 (2004) 22
18. Parmenon, C.; Viaud-Massuard, M.-C.; Guillard, J.; Dacquet, C.; Ktorza, A.; Caignard, D.-H. WO2006/079719, 2006.
19. Parmenon C., Guillard J., Caignard D.-H., Hennuyer N., Staels B., Audinot-Bouchez V., Boutin J.-A., Ktorza A., Dacquet C., and Viaud-Massuard M.-C. Bioorg. Med. Chem. Lett. 18 (2008) 1617
20. Cox G.G., Haigh D., Hindley R.M., Miller D.J., and Moody C.J. Tetrahedron Lett. 35 (1994) 3139
21. Henke B.R., Blanchard S.G., Brackeen M.F., Brown K.K., Cobb J.E., Collins J.L., Harrington W.W., Hashim M.A., Hull-Ryde E.A., Kaldor I., Kliewer S.A., Lake D.H., Leesnitzer L.M., Lehmann J.M., Lenhard J.M., Orband Miller L.A., Miller J.F., Mook R.A., Noble S.A., Oliver W., Parks D.J., Plunket K.J., Szewczk J.R., and Willson T.M. J. Med. Chem. 41 (1998) 5020
22. 2 anaesthesia. Plasma sample were prepared by centrifugation (2000g for 10 min), and stored at -20 °C. The mice were euthanized by cervical dislocation. For triglycerides and insulin, the percentage change in plasma level as calculated relative to the mean plasma level in the vehicle-treated mice. ANOVA, followed by Dunnett's comparison test (one tailed) was used to estimate the significant difference between the plasma triglycerides, insulin and delta body weight values from the control group and the individual compound-treated groups. The compound is considered active, at the specific dosage administered, if the difference in plasma levels had a P < 0.05. All compounds with a P > 0.05 were reported as inactive.